An oral anticoagulant reduces the prevention of venous thrombosis associated with cancer
Published the 20.12.2017 at 06h05
The risk of venous thrombosis is five-fold higher in the cancer patients. Also called phlebitis, is the formation of a clot in the blood. The hazards vary according to its location : a location proximal to a risk of embolism. For cancer patients, the existence of such a pathology is all the more dangerous that the drugs the caregiver may interfere with cancer treatments.
Importantly, these venous thrombi increase the risk of hospitalization and can lead to death. Often, in order to limit the side effects, the low molecular weight heparin is used in treatment with its injection under the skin daily. Researchers compared the effectiveness of this treatment, binding, treatment, edoxaban, an anti-coagulant treatment with direct oral.
Bleeding that is more frequent with the edoxaban
The study, published in the New England Journal of Medicine, lasted from July 2015 to December 2016. 1050 patients have participated and have been draws lots. A part of them received treatment with low molecular weight heparin, the other of the edoxaban. This treatment lasted between 6 and 12 months.
For both groups, the effectiveness is substantially the same, and edoxaban meets the conditions of non-inferiority, that is to say that its effectiveness is substantially equivalent to that of heparin. A recurrence of venous thrombosis occurred in 7.9% of patients on edoxaban and in 11.3% of patients on heparin. But the bleeding is a little more frequent under edoxaban, 6.9%, compared to 4% for heparin.
For all types of treatments, there are constraints, or higher risk.